Sung Ki-Chul, Cha Sung-Chul, Sung Joo-Wook, So Min-Suk, Byrne Christopher D
Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, #108, Pyung Dong, Jongro-Ku, Seoul 110-746, Republic of Korea.
Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, #108, Pyung Dong, Jongro-Ku, Seoul 110-746, Republic of Korea.
Nutr Metab Cardiovasc Dis. 2014 Mar;24(3):256-62. doi: 10.1016/j.numecd.2013.07.005. Epub 2013 Oct 9.
Whether obesity increases risk of cardiovascular disease (CVD) and fatty liver because of the co-existence of other risk factors is uncertain. We investigated odds ratios (ORs) for: a) a measure of pre-clinical atherosclerosis and b) fatty liver, in metabolically healthy obese (MHO) subjects, metabolically abnormal obese (MAO) subjects and metabolically abnormal non obese subjects (MANO), using a metabolically healthy non obese (MHNO) group as the reference.
14,384 South Koreans from an occupational cohort underwent cardiac computed tomography (CT) estimation of CAC score, liver ultrasound determination of fatty liver, and measurement of cardiovascular risk factors. Pre-clinical atherosclerosis was defined by a CAC score >0. We used logistic regression to determine ORs for CAC >0, and fatty liver in MHO, MAO and MANO subjects (reference group MHNO). There was no increase in OR for CAC score >0 (OR = 0.93, [95% CIs 0.67,1.31], p = 0.68), in the MHO group, whereas there was an increase in the ORs for CAC score >0 in the MAO, and MANO groups (OR = 1.64 [95% CI 1.36,1.98], p < 0.001) and (OR = 1.38 [95% CI 1.17,1.64], p < 0.001), respectively. In contrast, for fatty liver, there was an increase in OR in each group (OR = 3.63 [95% CI 3.06, 4.31] p < 0.001); (OR = 5.89 [5.18,6.70] p < 0.001); and (OR = 1.83 [95% CI 1.69,2.08]) in the MHO, MAO group and MANO groups respectively.
MHO subjects are at risk of fatty liver but attenuated risk of pre-clinical atherosclerosis. Both MAO and MANO subjects are at risk of fatty liver and pre-clinical atherosclerosis.
肥胖是否由于其他危险因素的共存而增加心血管疾病(CVD)和脂肪肝的风险尚不确定。我们以代谢健康的非肥胖(MHNO)组作为对照,调查了代谢健康的肥胖(MHO)受试者、代谢异常的肥胖(MAO)受试者和代谢异常的非肥胖受试者(MANO)中:a)临床前期动脉粥样硬化指标和b)脂肪肝的比值比(OR)。
来自一个职业队列的14384名韩国人接受了心脏计算机断层扫描(CT)以评估冠状动脉钙化(CAC)评分、肝脏超声检查以确定脂肪肝情况,并测量了心血管危险因素。临床前期动脉粥样硬化定义为CAC评分>0。我们使用逻辑回归来确定MHO、MAO和MANO受试者(参照组MHNO)中CAC>0和脂肪肝的OR。MHO组中CAC评分>0的OR没有增加(OR = 0.93,[95%置信区间0.67,1.31],p = 0.68),而MAO组和MANO组中CAC评分>0的OR增加(分别为OR = 1.64 [95%置信区间1.36,1.98],p < 0.001)和(OR = 1.38 [95%置信区间1.17,1.64],p < 0.001)。相反,对于脂肪肝,每组的OR均增加(MHO组为OR = 3.63 [95%置信区间3.06, 4.31] p < 0.001);(MAO组为OR = 5.89 [5.18,6.70] p < 0.001);(MANO组为OR = 1.83 [95%置信区间1.69,2.08])。
MHO受试者有患脂肪肝的风险,但临床前期动脉粥样硬化风险降低。MAO和MANO受试者均有患脂肪肝和临床前期动脉粥样硬化的风险。